Safety and efficacy of biologic therapies for inflammatory bowel disease in patients with primary sclerosing cholangitis: A retrospective multi-center cohort study
-
- STATUS
- Not Recruiting
Summary
The purpose of this study is to compare Vedolizumab to other biologic agents by measuring adverse events, including infections, hospitalizations, mortality, liver transplants, etc. in patients that have both inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC).
Description
The purpose of this study is to compare Vedolizumab to other biologic agents by measuring adverse events, including infections, hospitalizations, mortality, liver transplants, etc. in patients that have both inflammatory bowel disease (IBD) and primary sclerosing cholangitis (PSC).
Details
| Condition | inflammatory bowel disease |
|---|---|
| Age | 100years or below |
| Clinical Study Identifier | TX7394 |
| Last Modified on | 19 February 2024 |
Similar trials to consider
Not finding what you're looking for?
Sign up as a volunteer to stay informed
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.
Sign up as volunteerStudy Definition
WikipediaAdd a private note
- Select a piece of text.
- Add notes visible only to you.
- Send it to people through a passcode protected link.